30例学校恐惧症人格和情绪特征研究

目的：探讨学校恐惧症的临床特征。方法：对30例学校恐惧症患儿（研究组）和30名正常对照儿童（对照组）进行艾森克个性问卷（EPQ）,儿童焦虑性情绪障碍筛选量表（SCARED）,焦虑自评量表（SAS）及抑郁自评量表（SDS）评估。结果：研究组患儿EPQ结果显示神经质得分显著高于对照组,掩饰程度得分显著低于对照组（P均〈0.05）;SCARED、SAS、SDS的评估显示,与对照组相比,研究组存在明显焦虑和抑郁症状（P〈0.05）。结论：学校恐惧症患儿可能具有神经症的个性特点,普遍存在焦虑和抑郁症状。     

心理干预对全脑血管造影术患者的影响

目的探讨全脑血管造影术对患者情绪的影响及心理干预对其的作用。方法采用社会心理因素调查表对81例行全脑血管造影术的患者进行调查,并用汉密尔顿焦虑量表（HAMA）、汉密尔顿抑郁量表（HAMD）、焦虑自评量表（SAS）和抑郁自评量表（SDS）比较心理干预前后患者的焦虑、抑郁情况及不同疾病患者的焦虑、抑郁情况。结果患者主要由于对诊疗方法不了解及担心手术失败而造成心理压力;心理干预后患者的焦虑、抑郁情况得到改善（P〈0．01）;不同疾病患者术前的焦虑情况有显著差别（P〈0．05）,心理干预后差异消失。结论心理干预可有效缓解行全脑血管造影术患者的焦虑、抑郁情绪,应作为全脑血管造影术的辅助治疗措施之一。     

68例开放管理的女性精神分裂症患者陪护家属的心理状况及健康教育的效果分析

目的探讨开放管理女性精神分裂症住院患者陪护家属的心理状况及健康教育的效果。方法将132例开放管理女性精神分裂症住院患者陪护家属随机分为两组,研究组68例,对照组64例,研究组实施健康教育,对照组未实施。采用自编的调查表对两组陪护家属在患者入院时进行调查;并采用抑郁自评量表（SDS）和焦虑自评量表（SAS）对两组家属在患者入院3 d内和健康教育结束时分别进行评定。结果开放管理女性精神分裂症住院患者陪护家属的心理状况不容乐观,均存在一定的焦虑、抑郁情绪,且对疾病的认知不同,对医生的干预性治疗建议的领悟接受不一。研究组在健康教育结束时抑郁自评量表和焦虑自评量表评分均有显著下降（P〈0.01）,均显著低于对照组（P〈0.01）。结论对开放管理女性精神分裂症住院患者陪护家属及时进行健康教育,能改善家属的心理状况,提高家属对疾病的正确认识,有助于提高患者的治疗依从性,利于患者的早日康复。     

健康教育对Ⅱ型糖尿病患者抑郁情绪的影响

目的观察健康教育与心理干预对II型糖尿病患者抑郁情绪、血糖代谢的影响。方法将80例糖尿病患者按就诊先后随机分为研究组和对照组。研究组在口服常规降糖药物的基础上,进行健康教育及心理干预,总疗程3个月,治疗前后进行Zung抑郁自评量表（SDS）,Zung焦虑自评量表（SAS）、汉密顿抑郁量表（HAMD）评估,进行空腹血糖（FPG）,餐后2小时血糖（2HPG）、糖化血红蛋白（HbA1C）,血脂（TC、TG、HDL-C）体重指数（BMI）等临床指标检测,并进行同期组间比较。结果经过健康教育与心理干预治疗3个月后,研究组抑郁、焦虑量表评分显著低于对照组（P〈0.05）。临床指标改善亦明显优于对照组（P〈0.05）。结论健康教育与心理干预有助于II型糖尿病患者抑郁情绪的改善,能有效提高临床控制效果。     

接受冠状动脉支架置入治疗者的心理状态分析

目的：探讨冠状动脉粥样硬化性心脏病(简称冠心病)患者接受冠状动脉支架置入前后焦虑、抑郁水平。 方法：汇总文献分析冠心病患者发生抑郁、焦虑情绪障碍机制。临床验证病例选择2008-03/12住院接受冠状动脉内支架置入治疗的冠心病患者61例为研究组,同时期选择与患者相匹配的新乡市某区居民61例为对照组,由经过培训的心理工作人员对研究组于手术前后1周内进行焦虑自评量表、抑郁自评量表调查。 结果：早期的研究提出了抑郁对冠心病可能存在的影响机制,包括行为因素如患者对治疗的依从性差等和生理因素如心律失常等。近期又提出了一些新的生理机制,如心脏自主神经功能改变、炎症过程、血栓形成、内皮功能障碍、遗传因素等。冠心病患者的焦虑情绪障碍发生机制十分复杂,目前认为与遗传、行为类型、环境因素等有关。临床验证结果：研究组手术前焦虑自评量表、抑郁自评量表评分均高于对照组第1次评分(P < 0.01)。研究组手术后焦虑自评量表、抑郁自评量表得分与手术前比较,差异无显著性意义(P > 0.05)。对照组第2次焦虑自评量表、抑郁自评量表得分与第1次比较,差异无显著性意义(P > 0.05)。 结论：冠状动脉支架治疗者焦虑、抑郁情绪明显。在接受支架置入治疗时,还要积极配合心理社会干预,帮助患者改善焦虑、抑郁情绪,以促进其疾病康复,提高生活质量。     

首发儿童精神分裂症患者母亲抑郁症的调查

为探讨独生男孩首次患精神分裂症后,其母伴抑郁症状的临床特点,对38例患儿母亲进行症状自评量表（SCL－90）、抑郁自评量表（SDS）和汉密尔顿抑郁量表（HAMD）评定。同时选取年龄、文化程度、职业相匹配的38例健康独生男孩的母亲为对照。结果：研究组常伴有抑郁症状,三种量表总分均明显高于对照组（P＜0．001）。提示,对伴抑郁症状（患儿）母亲应予心理和抗抑郁药物治疗,对存在心身健康问题（患儿）母亲给予咨询、指导和社会心理支持。     

基于知识宣教的心理干预对脑损伤患儿父母焦虑及抑郁情绪的影响

目的探讨基于知识宣教的心理干预对脑损伤患儿父母焦虑及抑郁情绪的影响。方法选取2013年9月至2016年9月期间我院确诊治疗的脑损伤患儿父母100例,依据随机数表法随机分为心理组和常规组,每组50例,常规组父母给予常规指导干预,心理组父母在此基础上给予基于知识宣教的心理干预,采用焦虑自评量表(SAS)和抑郁自评量表(SDS)评估焦虑及抑郁情绪,采用本院自制《脑损伤患儿护理知识问卷》评估护理知识掌握程度,统计分析所有患儿父母护理知识掌握程度和干预前、干预后1、4、7d的焦虑及抑郁情绪情况。结果心理组父母干预后1、4、7d的SAS得分明显低于常规组,有统计学差异(P0.05);心理组父母干预后1、4、7d的SDS得分明显低于常规组,有统计学差异(P0.05);心理组父母护理知识掌握率明显高于常规组,有统计学差异(P0.05)。结论基于知识宣教的心理干预可有效改善脑损伤患儿父母焦虑及抑郁情绪,及可有效提高其护理知识掌握程度,有利于患儿治疗的顺利进行,值得临床作进一步推广。     

脑瘫患儿父母不良情绪对患儿康复的影响

目的探讨脑瘫患儿父母不良情绪对患儿康复的影响。方法对我院2006-05-2007-05诊治的45例脑瘫患儿的父母（观察组）采用医院焦虑抑郁量表（HAD）进行焦虑、抑郁情绪调查,并与45例非脑瘫患儿的父母（对照组）进行比较。结果 观察组焦虑分值（A分值）、抑郁分值（D分值）和总分值（T分值）分别为（10.02±2.57）分、（10.48±2.61）分和（20.49±3.65）分,均显著高于对照组的（8.15±2.37）分、（7.79±2.23）分和（15.91±3.52）分,2组比较差异有统计学意义（P〈0.05）。结论 脑瘫患儿的父母与非脑瘫患儿父母比较有更多的抑郁和焦虑情绪,而这些不良情绪会严重影响患儿的康复。加强脑瘫患儿父母的社会心理干预,以利于脑瘫患儿的康复。     

创伤后应激障碍患者的焦虑抑郁与血浆皮质醇水平观察

目的观察创伤后应激障碍（PTSD）患者的焦虑抑郁症状与血浆皮质醇水平的变化。方法以PTSD患者31例为研究组,应用抑郁自评量表（SDS）和焦虑自评量表（SAS）为工具,于入院后0周、1周末和4周末分别评定患者的抑郁焦虑症状,并同步测定血浆皮质醇水平,观察其抑郁焦虑程度及血浆皮质醇水平的变化,并与30名健康者作对照。结果研究组的SDS、SAS总分在发病期（0周和1周末）均显著升高（P〈0.01）,好转后恢复至正常水平。与对照组比较,研究组的血浆皮质醇水平在发病期显著升高（P〈0.01）,随着创伤程度的减轻而恢复正常。研究组血浆皮质醇水平的变化（0周与1周末,1周末与4周末）与SDS、SAS总分的变化无相关性（P〉0.05）。结论PTSD患者在发病期存在不同程度的焦虑抑郁情绪,伴血浆皮质醇水平升高,此期需给予相应的药物治疗和心理干预。     

2型糖尿病患者负性情绪研究

目的：探讨负性情绪与2型糖尿病的关系。方法：对51例2型糖尿病患者与50例正常对照者进行负性情绪比较，采用生活事件量表（LES）、社会支持评定量表（SSRS）、症状自评量表（SCL-90）、抑郁自评量表（SDS）及焦虑自评量表（SAS）测评。结果：与对照组比较，糖尿病组的负性生活事件刺激量和总刺激量得分均显著较高（P均〈0．01）；而社会支持总分、主观支持分及支持利用度分均显著较低（P均〈0．01）。糖尿病组SCL-90总分及躯体化、人际关系敏感、抑郁、焦虑、敌对、恐惧6个因子分与SDS、SAS评分均显著高于对照组（P〈0．05或P〈0．01）。结论：2型糖尿病患者存在明显的负性情绪，有针对性的心理干预可能对其防治起重要作用。     

社交焦虑障碍患者的注意偏向研究

目的探索社交焦虑障碍（SAD）患者注意偏向的特点。方法收集明确诊断为SAD，同时汉密尔顿抑郁量表（HAMD）总分小于20分的患者共30例，并设正常对照组共30例。进行一般人口学资料调查表、Liebowitz社交焦虑量表（LSAS）和数字划销测验检查。结果SAD患者在HAMD、LSAS的得分明显高于对照组（P〈0．01）。数字划销测验中，SAD组的粗分158．0±23．6、失误分17．6±12．8、得分140．6±31．7、失误率12．1±12．1，对照组的粗分179．4±13．2、失误分11．3±d．0、得分168．1±13．9、失误率6．3±2．3，两组的差异有统计学意义（P〈0．05），其中粗分和得分与LSAS显著相关（P〈0．05）。结论社交焦虑障碍患者对数字信息，也会发生注意偏向，注意的偏向与当前关注的内容有关。     

蒙特利尔认知评估量表在帕金森病认知障碍患者中的应用价值

目的 分析蒙特利尔认知评估(MoCA)量表(中文版)在筛查帕金森病(PD)患者中认知障碍的应用价值.方法 使用RoSA编制的,根据年龄及教育程度调整的MMSE分界值筛出整体认知功能正常的213例PD患者,并进一步使用MoCA量表对其进行分组,MoCA评分≥26分的PD患者入PD认知正常组(PD-NC组),MoCA评分<26分的PD患者入PD认知损害组(PD-CI组).比较2组患者MoCA各分测验分数的差异及认知功能改变的特点,并应用单因素及多元Logistic回归分析PD患者认知损害的影响因素.结果 (1)PD组患者中52.6%(112/213)的患者MoCA评分<26分;(2)与PD-NC组比较,PD-CI组在MoCA视空间和执行、命名、注意力、语言、抽象、延迟回忆、定向分测验中得分诸项比较均有统计学意义;(3)Logistic回归分析结果显示,低文化程度是PD患者认知损害的影响因素(OR:0.72,95%CI0.64～0.81,P<0.05).结论 MMSE正常者中仍然存在相当比例的患者MoCA评分异常.因此,临床上建议使用MoCA对PD患者认知水平进行测试,在患者未达到PD痴呆时,应结合患者的教育水平及时发现并处理患者认知损害症状,使PD患者得到及时治疗并能提高生活质量.

Abstract：

Objective To examine the application of Montreal Cognitive Assessment (MoCA) in Parkinson' s disease (PD) patients with normal general cognitive function by Mini-Mental State Examination (MMSE) evaluation.Methods PD patients were examined with MMSE, and those having a normal ageand education-adjusted MMSE score were included in the further study of MoCA testing.The patients with MoCA score not less than 26 were selected into normal control PD-NC group, and the patients with less than 26 into cognitive impaired PD-CI group.Scores of MoCA subtests were used in PD-CI group and PD-NC group to characterize cognitive changes in PD patients with mild cognitive impairment (MCI).MoCA score in PD-CI group used as dependent variable, and sex, educational level, age, course of disease, Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA), Self-rating depression Scale (SDS), Self-rating Anxiety Scale (SAS) and Unified Parkinson' s Disease Rating Scale (UPDRS) were used as independent variable, the risk factors of CI in PD patients was analysed by Linear Regression Analysis.Results There are 52.6% (112/213) PD patients with MMSE ≥ 26 while their MoCA < 26.Significant differences were observed in subtests of MoCA in visuospatial, executive, naming, attention,language, abstract, delayed recall and orientation between PD-CI group and PD-NC group (all P <0.01).Univariate and multivariate regression analysis showed that educational level is the most significant factor in PD-CI (OR:0.72, 95% CI 0.64-0.81, P < 0.05).Conclusions There is a high proportion of PD patients whose MMSE test showed normal but MoCA test showed cognitive impairment.MoCA examination was used to detect cognitive function of PD patients.Furthermore we suggest consider the education level in PD patients when evaluate their cognitive function.     

Case series: brief parent-child group therapy for childhood anxiety disorders using a manual-based cognitive-behavioral technique

OBJECTIVE: To report on a brief parent-child group therapy program for children with anxiety disorders. METHOD: Twenty-four children with an anxiety disorder and their parents participated in a 10-session treatment. Children were evaluated at pretreatment (T1), posttreatment (T2), 12-month follow-up (T3), and 36-month follow-up (T4). Ten children were also assessed on entering a waiting period (T0). RESULTS: There were no significant symptomatic changes between T0 and T1. Anxiety symptoms decreased significantly during the treatment and follow-up periods. Depressive symptoms changed only during the follow-up period. The percentage of children with no current anxiety disorder was 71% at T2 and 91% at T4. Children of mothers with an anxiety disorder improved more than children of nonanxious mothers, whereas the anxiety level of anxious mothers remained stable. CONCLUSIONS: Brief parent-child group psychotherapy may serve as a time-limited, cost-effective, and efficient intervention.     

焦虑障碍患者健康行为水平调查及干预

目的探讨焦虑障碍患者的健康行为水平和综合干预的效果。方法选取80例符合《精神障碍诊断与统计手册(第5版)》(DSM-5)焦虑障碍诊断标准的门诊患者作为研究组,在社区抽签筛选80例健康成人作为健康对照组,采用健康促进生活方式量表Ⅱ(HPLP-Ⅱ)和世界卫生组织生活质量评定量表简表(WHOQOL-BREF)分别评定两组的健康行为水平和生活质量。采用随机数字表法将研究组患者分为干预组和对照组,对干预组进行随访、运动、阅读、心理治疗等行为干预6个月,对照组仅接受一般性心理治疗。采用HPLP-Ⅱ、WHOQOL-BREF、汉密尔顿焦虑量表(HAMA)进行评定,比较干预前后两组HPLP-Ⅱ、WHOQOL-BREF、HAMA总评分及6个月内的疾病复发率。结果研究组HPLP-Ⅱ总评分和自我实现、运动和锻炼、人际关系、压力处理四个分量表评分及WHOQOL-BREF总评分低于健康对照组(P0.05);干预后干预组的HPLP-Ⅱ总评分及运动和锻炼、人际关系、压力处理3个分量表评分及WHOQOL-BREF总评分均较干预前高(P0.05),HAMA评分低于干预前(P0.05),以上与对照组比较差异有统计学意义(P0.05),干预组疾病复发率低于对照组(P0.05)。结论焦虑障碍患者健康行为和生活质量水平低于健康人群,通过综合行为干预,可提高其健康行为水平和生活质量,改善焦虑症状,减少复发。     

Effectiveness of a meditation-based stress management program as an adjunct to pharmacotherapy in patients with anxiety disorder

OBJECTIVE: The objective of this study was to examine the effectiveness of a meditation-based stress management program in patients with anxiety disorder. METHODS: Patients with anxiety disorder were randomly assigned to an 8-week clinical trial of either a meditation-based stress management program or an anxiety disorder education program. The Hamilton Anxiety Rating Scale (HAM-A), the Hamilton Depression Rating Scale (HAM-D), the State-Trait Anxiety Inventory (STAI), the Beck Depression Inventory, and the Symptom Checklist--90-Revised (SCL-90-R) were used to measure outcome at 0, 2, 4, and 8 weeks of the program. RESULTS: Compared to the education group, the meditation-based stress management group showed significant improvement in scores on all anxiety scales (HAM-A, P=.00; STAI state, P=.00; STAI trait, P=.00; anxiety subscale of SCL-90-R, P=.00) and in the SCL-90-R hostility subscale (P=.01). Findings on depression measures were inconsistent, with no significant improvement shown by subjects in the meditation-based stress management group compared to those in the education group. The meditation-based stress management group did not show significant improvement in somatization, obsessive-compulsive symptoms, and interpersonal sensitivity scores, or in the SCL-90-R phobic anxiety subscale compared to the education group. CONCLUSIONS: A meditation-based stress management program can be effective in relieving anxiety symptoms in patients with anxiety disorder. However, well-designed, randomized, and controlled trials are needed to scientifically prove the worth of this intervention prior to treatment.     

Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder.

OBJECTIVE: The study compared the safety and efficacy of sertraline, a selective serotonin reuptake inhibitor, and placebo in the treatment of generalized anxiety disorder in children and adolescents. METHOD: The study subjects were 22 children and adolescents age 5-17 years who met the DSM-IV criteria for generalized anxiety disorder according to the Anxiety Disorders Interview Schedule for Children-Revised and who had a Hamilton Anxiety Rating Scale score > or = 16. The patients underwent a 2-3-week prestudy evaluation period, followed by a 9-week double-blind treatment phase in which they were randomly assigned in blocks of four to receive either sertraline or pill placebo. The maximum dose of sertraline was 50 mg/day. Primary outcome measures were the Hamilton anxiety scale and the Clinical Global Impression scale. RESULTS: The Hamilton anxiety scale total score, psychic factor, and somatic factor and the Clinical Global Impression severity and improvement scales showed significant differences with treatment in favor of sertraline over placebo beginning at week 4. Self-report measures reflected these results at the end of treatment. CONCLUSIONS: The results of this double-blind, placebo-controlled trial suggest that sertraline at the daily dose of 50 mg is safe and efficacious for the treatment of generalized anxiety disorder in children and adolescents.     

Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials

OBJECTIVE: The authors evaluated the efficacy, safety, and tolerability of extended-release venlafaxine in the treatment of pediatric generalized anxiety disorder. METHOD: Two randomized, double-blind, placebo-controlled trials were conducted at 59 sites in 2000 and 2001. Participants 6 to 17 years of age who met DSM-IV criteria for generalized anxiety disorder received a flexible dosage of extended-release venlafaxine (N=157) or placebo (N=163) for 8 weeks. The primary outcome measure was the composite score for nine delineated items from the generalized anxiety disorder section of a modified version of the Schedule for Affective Disorders and Schizophrenia for School-Age Children, and the primary efficacy variable was the baseline-to-endpoint change in this composite score. Secondary outcome measures were overall score on the nine delineated items, Pediatric Anxiety Rating Scale, Hamilton Anxiety Rating Scale, Screen for Child Anxiety Related Emotional Disorders, and the severity of illness and improvement scores from the Clinical Global Impression scale (CGI). RESULTS: The extended-release venlafaxine group showed statistically significant improvements in the primary and secondary outcome measures in study 1 and significant improvements in some secondary outcome measures but not the primary outcome measure in study 2. In a pooled analysis, the extended-release venlafaxine group showed a significantly greater mean decrease in the primary outcome measure compared with the placebo group (-17.4 versus -12.7). The response rate as indicated by a CGI improvement score <3 was significantly greater with extended-release venlafaxine than placebo (69% versus 48%). Common adverse events were asthenia, anorexia, pain, and somnolence. Statistically significant changes in height, weight, blood pressure, pulse, and cholesterol levels were observed in the extended-release venlafaxine group. CONCLUSIONS: Extended-release venlafaxine may be an effective, well-tolerated short-term treatment for pediatric generalized anxiety disorder.     

Risperidone in children with autism: randomized, placebo-controlled, double-blind study

Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism. We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior (aggressiveness, hyperactivity, irritability), social and emotional responsiveness, and communication skills. We conducted a randomized, double-blind, placebo-controlled trial with 40 consecutive children with autism, whose ages ranged from 2 to 9 years, who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months. Autism symptoms were monitored periodically. The outcome variables were total scores on the Childhood Autism Rating Scale (CARS) and the Children's Global Assessment Scale (CGAS) after 6 months. Of the 40 children enrolled, 39 completed the trial over a period of 18 months; 19 received risperidone, and 20 received placebo. In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively). Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression. Risperidone was associated with increased appetite and a mild weight gain, mild sedation in 20%, and transient dyskinesias in three children. Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated.     

经颅重复磁刺激辅助治疗老年焦虑症继发睡眠障碍的效果观察

目的 探讨米氮平合用经颅重复磁刺激法治疗伴睡眠障碍的老年焦虑症的疗效.方法 将100例符合“老年焦虑症”诊断标准并伴有失眠的患者随机分为研究组（米氮平合并经颅重复磁刺激法）和对照组（单用米氮平）各50例.观察8周.治疗前及治疗后第2,4,8周采用汉密尔顿焦虑量表（HAMA）、焦虑自评量表（SAS）、抑郁自评量表（SDS）评定焦虑和抑郁症状;治疗前及治疗第8周采用多导睡眠监测技术（PSG）和匹兹堡睡眠质量指数量表（PSQI）评定睡眠状况.结果 （1）两组临床疗效有效率分别为87.23％和68.89％,两组比较差异有统计学意义（x2=4.55,P＜0.05）;（2）治疗后4、8周后,研究组HAMA、SAS及SDS分值量表分值与对照组比较较低,且差异有统计学意义（t分别为3.997 3,4.937 7,3.359 9;P＜0.05）;（3）治疗后研究组实际睡眠总时间、睡眠潜伏期、REM潜伏期、REM睡眠比例、夜间觉醒次数、觉醒总时间评分结果与对照组比较差异有统计学意义（t分别为3.565 6,3.105 7,2.705 7,2.699 1,3.614 9,19.898 8;P＜0.05）;（4）治疗后研究组PSQI评分低于对照组,两组比较差异有统计学意义（t=3.327 8,P＜ 0.05）;（5）两组不良反应的发生率分别为10.64％和17.78％,经比较差异无统计学意义（x2=0.97,P＞0.05）.结论 米氮平合用经颅重复磁刺激法治疗老年焦虑症伴发的睡眠障碍有较好的效果.     

Effect of clorazepate on depressed mood in anxious patients

A double-blind, placebo-controlled study of clorazepate in the treatment of 189 patients diagnosed with generalized anxiety disorder was conducted to evaluate the efficacy of an anxiolytic on the depressed-mood component of anxiety. Clorazepate-treated patients with concomitant high levels of depressed mood, defined as a score of 60 or above on the Zung Self-Rating Depression Scale (SDS), showed significant improvement of anxiety symptomatology, as measured by the Hamilton Rating Scale for Anxiety and the Zung Self-Rating Anxiety Scale, and of depressed mood, as measured by the SDS, compared with placebo-treated patients (all p values less than .01).